Last reviewed · How we verify
Vincristine + Carboplatin + Etoposide
Vincristine + Carboplatin + Etoposide is a Vinca alkaloid, platinum-based alkylating agent, topoisomerase inhibitor Small molecule drug developed by St. Jude Children's Research Hospital. It is currently in Phase 3 development for Small cell lung cancer, Non-small cell lung cancer, Hodgkin lymphoma. Also known as: Oncovin + Paraplatin + VP-16.
Vincristine is a vinca alkaloid that inhibits microtubule formation, disrupting cell division. Carboplatin is a platinum-based alkylating agent that cross-links DNA, causing cell death. Etoposide is a topoisomerase inhibitor that prevents DNA replication and transcription.
Vincristine is a vinca alkaloid that inhibits microtubule formation, disrupting cell division. Carboplatin is a platinum-based alkylating agent that cross-links DNA, causing cell death. Etoposide is a topoisomerase inhibitor that prevents DNA replication and transcription. Used for Small cell lung cancer, Non-small cell lung cancer, Hodgkin lymphoma.
At a glance
| Generic name | Vincristine + Carboplatin + Etoposide |
|---|---|
| Also known as | Oncovin + Paraplatin + VP-16 |
| Sponsor | St. Jude Children's Research Hospital |
| Drug class | Vinca alkaloid, platinum-based alkylating agent, topoisomerase inhibitor |
| Target | Microtubules, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Vincristine works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis. Carboplatin, on the other hand, forms platinum-DNA adducts that interfere with DNA replication and transcription, ultimately causing cell death. Etoposide inhibits topoisomerase II, an enzyme that unwinds DNA during replication and transcription, leading to DNA damage and cell death.
Approved indications
- Small cell lung cancer
- Non-small cell lung cancer
- Hodgkin lymphoma
- Testicular cancer
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Infection
- Hypersensitivity reaction
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (PHASE1)
- A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) (PHASE3)
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vincristine + Carboplatin + Etoposide CI brief — competitive landscape report
- Vincristine + Carboplatin + Etoposide updates RSS · CI watch RSS
- St. Jude Children's Research Hospital portfolio CI
Frequently asked questions about Vincristine + Carboplatin + Etoposide
What is Vincristine + Carboplatin + Etoposide?
How does Vincristine + Carboplatin + Etoposide work?
What is Vincristine + Carboplatin + Etoposide used for?
Who makes Vincristine + Carboplatin + Etoposide?
Is Vincristine + Carboplatin + Etoposide also known as anything else?
What drug class is Vincristine + Carboplatin + Etoposide in?
What development phase is Vincristine + Carboplatin + Etoposide in?
What are the side effects of Vincristine + Carboplatin + Etoposide?
What does Vincristine + Carboplatin + Etoposide target?
Related
- Drug class: All Vinca alkaloid, platinum-based alkylating agent, topoisomerase inhibitor drugs
- Target: All drugs targeting Microtubules, DNA
- Manufacturer: St. Jude Children's Research Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Small cell lung cancer
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Hodgkin lymphoma
- Also known as: Oncovin + Paraplatin + VP-16
- Compare: Vincristine + Carboplatin + Etoposide vs similar drugs
- Pricing: Vincristine + Carboplatin + Etoposide cost, discount & access